Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Breast Cancer

  Free Subscription


22.01.2018

1 AJR Am J Roentgenol
4 Ann Oncol
2 Ann Surg Oncol
4 BMC Cancer
1 BMJ
1 Breast Cancer
19 Breast Cancer Res Treat
3 Cancer
2 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
3 Cancer Res
1 Carcinogenesis
2 Clin Breast Cancer
1 Clin Cancer Res
1 Clin Exp Metastasis
2 Eur J Cancer
1 Eur Radiol
3 Int J Cancer
4 Int J Oncol
1 J Clin Oncol
3 J Natl Cancer Inst
2 JAMA
3 Lancet
4 Lancet Oncol
2 Nature
5 Oncogene
4 Oncol Rep
7 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. CARTER KJ, Castro F, Morcos RN
    Insights Into Breast Cancer Screening: A Computer Simulation of Two Contemporary Screening Strategies.
    AJR Am J Roentgenol. 2018 Jan 11:1-8. doi: 10.2214/AJR.17.18484.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. SOMASHEKHAR SP, Sepulveda MJ, Puglielli S, Norden AD, et al
    Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board.
    Ann Oncol. 2018 Jan 9. pii: 4781689. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. VAN BOCKSTAL M, Libbrecht L, Floris G, Lambein K, et al
    Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?
    Ann Oncol. 2017;28:2317.
    PubMed     Text format    

  4. TURNER NC, Finn RS, Martin M, Im SA, et al
    Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases.
    Ann Oncol. 2018 Jan 11. pii: 4802189. doi: 10.1093.
    PubMed     Text format     Abstract available

  5. ABBOSH C, Swanton C, Birkbak NJ
    Circulating tumor DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
    Ann Oncol. 2018 Jan 17. pii: 4815740. doi: 10.1093.
    PubMed     Text format    


    Ann Surg Oncol

  6. HAQUE W, Verma V, Naik N, Butler EB, et al
    Metaplastic Breast Cancer: Practice Patterns, Outcomes, and the Role of Radiotherapy.
    Ann Surg Oncol. 2018 Jan 10. pii: 10.1245/s10434-017-6316.
    PubMed     Text format     Abstract available

  7. JANG N, Kwon HJ, Park MH, Kang SH, et al
    Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
    Ann Surg Oncol. 2018 Jan 12. pii: 10.1245/s10434-017-6332.
    PubMed     Text format     Abstract available


    BMC Cancer

  8. BERNAL-ESTEVEZ DA, Garcia O, Sanchez R, Parra-Lopez CA, et al
    Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy.
    BMC Cancer. 2018;18:77.
    PubMed     Text format     Abstract available

  9. YU SJ, Yang L, Hong Q, Kuang XY, et al
    MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer.
    BMC Cancer. 2018;18:74.
    PubMed     Text format     Abstract available

  10. PARK JS, Lee ST, Nam EJ, Han JW, et al
    Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
    BMC Cancer. 2018;18:83.
    PubMed     Text format     Abstract available

  11. ELWOOD JM, Tin Tin S, Kuper-Hommel M, Lawrenson R, et al
    Obesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort study.
    BMC Cancer. 2018;18:76.
    PubMed     Text format     Abstract available


    BMJ

  12. VAIDYA JS, Massarut S, Vaidya HJ, Alexander EC, et al
    Rethinking neoadjuvant chemotherapy for breast cancer.
    BMJ. 2018;360:j5913.
    PubMed     Text format    


    Breast Cancer

  13. HABYARIMANA T, Attaleb M, Mazarati JB, Bakri Y, et al
    Detection of human papillomavirus DNA in tumors from Rwandese breast cancer patients.
    Breast Cancer. 2018 Jan 19. pii: 10.1007/s12282-018-0831.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  14. KOOPMAN T, Buikema HJ, Hollema H, de Bock GH, et al
    Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-018-4669.
    PubMed     Text format     Abstract available


  15. 1st UK Interdisciplinary Breast Cancer Symposium-15th-16th January 2018.
    Breast Cancer Res Treat. 2018 Jan 10. pii: 10.1007/s10549-017-4585.
    PubMed     Text format    

  16. NOMURA SJO, Hwang YT, Gomez SL, Fung TT, et al
    Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jan 11. pii: 10.1007/s10549-017-4634.
    PubMed     Text format     Abstract available

  17. TAN Q, Wei C
    Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4648.
    PubMed     Text format    

  18. NUNCIA-CANTARERO M, Martinez-Canales S, Andres-Pretel F, Santpere G, et al
    Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4652.
    PubMed     Text format     Abstract available

  19. PAN Y, Heisig SR, von Blanckenburg P, Albert US, et al
    Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4637.
    PubMed     Text format     Abstract available

  20. PAN K, Hurria A, Chlebowski RT
    Breast cancer survivorship: state of the science.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-017-4650.
    PubMed     Text format     Abstract available

  21. CHENG J, Holland-Letz T, Wallwiener M, Surowy H, et al
    Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-018-4666.
    PubMed     Text format     Abstract available

  22. BAO T, Seidman A, Li Q, Seluzicki C, et al
    Living with chronic pain: perceptions of breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jan 19. pii: 10.1007/s10549-018-4670.
    PubMed     Text format     Abstract available

  23. MIJWEL S, Backman M, Bolam KA, Olofsson E, et al
    Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-018-4663.
    PubMed     Text format     Abstract available

  24. PEDERSON HJ, Hussain N, Noss R, Yanda C, et al
    Impact of an embedded genetic counselor on breast cancer treatment.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-017-4643.
    PubMed     Text format     Abstract available

  25. BREYER JZ, Wendland EM, Kops NL, Caleffi M, et al
    Assessment of potential risk factors for breast cancer in a population in Southern Brazil.
    Breast Cancer Res Treat. 2018 Jan 17. pii: 10.1007/s10549-017-4655.
    PubMed     Text format     Abstract available

  26. GARCIA GARRE E, Luengo Gil G, Montoro Garcia S, Gonzalez Billalabeitia E, et al
    Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-017-4656.
    PubMed     Text format     Abstract available

  27. FOSTIRA F, Saloustros E, Apostolou P, Vagena A, et al
    Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-018-4661.
    PubMed     Text format     Abstract available

  28. NI YB, Tsang JYS, Shao MM, Chan SK, et al
    GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-017-4645.
    PubMed     Text format     Abstract available

  29. JAKIMOVSKA M, Maleva Kostovska I, Popovska-Jankovic K, Kubelka-Sabit K, et al
    BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-017-4642.
    PubMed     Text format     Abstract available

  30. POORVU PD, Vaz-Luis I, Freedman RA, Lin NU, et al
    Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-018-4659.
    PubMed     Text format     Abstract available

  31. LAMBERTINI M, Fontanella C
    How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer?
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-017-4654.
    PubMed     Text format    

  32. ZHANG Y, Ji Y, Li J, Lei L, et al
    Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-018-4660.
    PubMed     Text format     Abstract available


    Cancer

  33. REEDER-HAYES KE, Wheeler SB, Baggett CD, Zhou X, et al
    Influence of provider factors and race on uptake of breast cancer gene expression profiling.
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31222.
    PubMed     Text format     Abstract available

  34. PILEWSKIE M, Morrow M
    Margins in breast cancer: How much is enough?
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31221.
    PubMed     Text format     Abstract available

  35. SIMON MS, Beebe-Dimmer JL, Hastert TA, Manson JE, et al
    Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative.
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31230.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  36. HONG CC, Sucheston-Campbell LE, Liu S, Hu Q, et al
    Genetic variants in immune-related pathways and breast cancer risk in African American women in the AMBER consortium.
    Cancer Epidemiol Biomarkers Prev. 2018 Jan 16. pii: 1055-9965.EPI-17-0434.
    PubMed     Text format     Abstract available

  37. BAGLIA ML, Tang MC, Malone KE, Porter P, et al
    Family History and Risk of Second Primary Breast Cancer after In Situ Breast Carcinoma.
    Cancer Epidemiol Biomarkers Prev. 2018 Jan 16. pii: 1055-9965.EPI-17-0837.
    PubMed     Text format     Abstract available


    Cancer Lett

  38. ZIELINSKA HA, Holly JMP, Bahl A, Perks CM, et al
    Inhibition of FASN and ERalpha signalling during hyperglycaemia-induced matrix-specific EMT promotes breast cancer cell invasion via a caveolin-1-dependent mechanism.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30050.
    PubMed     Text format     Abstract available

  39. GUO W, Hao B, Luo N, Ruan D, et al
    Early re-staging and molecular subtype shift surveillance of locally recurrent or metastatic breast cancer: A new PET/CT integrated precise algorithm.
    Cancer Lett. 2018 Jan 11. pii: S0304-3835(18)30041.
    PubMed     Text format     Abstract available


    Cancer Res

  40. NOUGAREDE A, Popgeorgiev N, Kassem L, Omarjee S, et al
    Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10.
    Cancer Res. 2018 Jan 12. pii: 0008-5472.CAN-17-0846.
    PubMed     Text format     Abstract available

  41. SARVI S, Patel H, Li J, Dodd GL, et al
    Kindlin-1 promotes pulmonary breast cancer metastasis.
    Cancer Res. 2018 Jan 12. pii: 0008-5472.CAN-17-1518.
    PubMed     Text format     Abstract available

  42. SAHA M, Kumar S, Bukhari S, Balaji SA, et al
    AMPK-AKT double negative feedback loop in breast cancer cells regulates their adaptation to matrix deprivation.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-2090.
    PubMed     Text format     Abstract available


    Carcinogenesis

  43. BRINTON LA, Figueroa JD, Ansong D, Nyarko KM, et al
    Skin Lighteners and Hair Relaxers as Risk Factors for Breast Cancer: Results from the Ghana Breast Health Study.
    Carcinogenesis. 2018 Jan 6. pii: 4792875. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  44. MORIKAWA A, Wang R, Patil S, Diab A, et al
    Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
    Clin Breast Cancer. 2017 Dec 21. pii: S1526-8209(17)30394.
    PubMed     Text format     Abstract available

  45. GORNSTEIN EL, Sandefur S, Chung JH, Gay LM, et al
    BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.
    Clin Breast Cancer. 2017 Dec 21. pii: S1526-8209(17)30680.
    PubMed     Text format    


    Clin Cancer Res

  46. YANG X, Pan Y, Qiu Z, Du Z, et al
    RNF126 as a biomarker of a poor prognosis in invasive breast cancer and CHK1 inhibitor efficacy in breast cancer cells.
    Clin Cancer Res. 2018 Jan 11. pii: 1078-0432.CCR-17-2242.
    PubMed     Text format     Abstract available


    Clin Exp Metastasis

  47. GAREAU AJ, Brien C, Gebremeskel S, Liwski RS, et al
    Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
    Clin Exp Metastasis. 2018 Jan 11. pii: 10.1007/s10585-018-9874.
    PubMed     Text format     Abstract available


    Eur J Cancer

  48. BRIER MJ, Chambless DL, Chen J, Mao JJ, et al
    Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
    Eur J Cancer. 2018 Jan 9. pii: S0959-8049(17)31485.
    PubMed     Text format     Abstract available

  49. RAPHAEL J, Desautels D, Pritchard KI, Petkova E, et al
    Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2018;91:38-46.
    PubMed     Text format     Abstract available


    Eur Radiol

  50. HORVAT JV, Durando M, Milans S, Patil S, et al
    Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis.
    Eur Radiol. 2018 Jan 12. pii: 10.1007/s00330-017-5202.
    PubMed     Text format     Abstract available


    Int J Cancer

  51. JOHN EM, Hines LM, Phipps AI, Koo J, et al
    Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) Study.
    Int J Cancer. 2018 Jan 13. doi: 10.1002/ijc.31258.
    PubMed     Text format     Abstract available

  52. TERVASMAKI A, Mantere T, Hartikainen JM, Kauppila S, et al
    Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31259.
    PubMed     Text format     Abstract available

  53. BUSUND M, Bugge NS, Braaten T, Waaseth M, et al
    Progestin-Only and Combined Oral Contraceptives and Receptor-Defined Premenopausal Breast Cancer Risk: The Norwegian Women and Cancer Study.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31266.
    PubMed     Text format     Abstract available


    Int J Oncol

  54. ABSMAIER M, Napieralski R, Schuster T, Aubele M, et al
    PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
    Int J Oncol. 2018 Jan 8. doi: 10.3892/ijo.2018.4241.
    PubMed     Text format     Abstract available

  55. YOU KS, Yi YW, Kwak SJ, Seong YS, et al
    Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    Int J Oncol. 2018 Jan 15. doi: 10.3892/ijo.2018.4244.
    PubMed     Text format     Abstract available

  56. NOWAK A, Grzegrzolka J, Kmiecik A, Piotrowska A, et al
    Role of nestin expression in angiogenesis and breast cancer progression.
    Int J Oncol. 2018;52:527-535.
    PubMed     Text format     Abstract available

  57. YEN MC, Huang YC, Kan JY, Kuo PL, et al
    S100B expression in breast cancer as a predictive marker for cancer metastasis.
    Int J Oncol. 2018;52:433-440.
    PubMed     Text format     Abstract available


    J Clin Oncol

  58. HOLOWATYJ AN, Cote ML, Ruterbusch JJ, Ghanem K, et al
    Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 17:JCO2017745448. doi: 10.1200/JCO.2017.74.5448.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  59. MOORE SC, Playdon MC, Sampson JN, Hoover RN, et al
    A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795343. doi: 10.1093.
    PubMed     Text format     Abstract available

  60. OZTURK TOPCU T, Jerzak KJ, Warner E
    RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2018 Jan 10. pii: 4797407. doi: 10.1093.
    PubMed     Text format    

  61. LASKY-SU JA, Zeleznik OA, Eliassen AH
    Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795354. doi: 10.1093.
    PubMed     Text format    


    JAMA

  62. BALLMAN KV, McCall LM, Giuliano AE
    Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer-Reply.
    JAMA. 2018;319:306-307.
    PubMed     Text format    

  63. UNO H, Hassett MJ, Wei LJ
    Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer.
    JAMA. 2018;319:306.
    PubMed     Text format    


    Lancet

  64. VAIDYA JS, Bulsara M, Wenz F, Tobias JS, et al
    Targeted radiotherapy for early breast cancer.
    Lancet. 2018;391:26-27.
    PubMed     Text format    

  65. CAMERON DA, Gelber RD, Procter M, Suter T, et al
    Concerns about cardiotoxicity in the HERA trial - Authors' reply.
    Lancet. 2018;390:2767-2768.
    PubMed     Text format    

  66. COLES CE, Haviland JS, Kirby AM, Titley J, et al
    Targeted radiotherapy for early breast cancer - Authors' reply.
    Lancet. 2018;391:27-28.
    PubMed     Text format    


    Lancet Oncol

  67. COPSON ER, Maishman TC, Tapper WJ, Cutress RI, et al
    Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Lancet Oncol. 2018 Jan 11. pii: S1470-2045(17)30891.
    PubMed     Text format     Abstract available

  68. GIANNI L, Bisagni G, Colleoni M, Del Mastro L, et al
    Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Lancet Oncol. 2018 Jan 8. pii: S1470-2045(18)30001.
    PubMed     Text format     Abstract available

  69. PIVOT X, Cox DG
    A new era for treatment development in HER2-positive breast cancer.
    Lancet Oncol. 2018 Jan 8. pii: S1470-2045(18)30002.
    PubMed     Text format    

  70. FASCHING PA
    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
    Lancet Oncol. 2018 Jan 11. pii: S1470-2045(18)30008.
    PubMed     Text format    


    Nature

  71. GUPTA S
    Trials and tribulations.
    Nature. 2017;548:S28-S31.
    PubMed     Text format    

  72. ABDERRAHMAN B, Jordan VC
    Telling details of breast-cancer recurrence.
    Nature. 2018;553:155.
    PubMed     Text format    


    Oncogene

  73. MORATH I, Jung C, Leveque R, Linfeng C, et al
    Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer.
    Oncogene. 2018 Jan 11. pii: 10.1038/s41388-017-0030.
    PubMed     Text format     Abstract available

  74. MARTINEZ-ORDONEZ A, Seoane S, Cabezas P, Eiro N, et al
    Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.
    Oncogene. 2018 Jan 11. pii: 10.1038/s41388-017-0036.
    PubMed     Text format     Abstract available

  75. NAVANEETHAKRISHNAN S, Rosales JL, Lee KY
    Loss of Cdk5 in breast cancer cells promotes ROS-mediated cell death through dysregulation of the mitochondrial permeability transition pore.
    Oncogene. 2018 Jan 19. pii: 10.1038/s41388-017-0103.
    PubMed     Text format     Abstract available

  76. IKINK GJ, Boer M, Bakker ERM, Vendel-Zwaagstra A, et al
    Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.
    Oncogene. 2018 Jan 12. pii: 10.1038/s41388-017-0031.
    PubMed     Text format     Abstract available

  77. LEE GH, Yoo KC, An Y, Lee HJ, et al
    FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5/NOTCH2 signaling node.
    Oncogene. 2018 Jan 19. pii: 10.1038/s41388-017-0114.
    PubMed     Text format     Abstract available


    Oncol Rep

  78. ZHAO M, Wang Y, Du C, Liu Y, et al
    Aspirin and metformin exhibit antitumor activity in murine breast cancer.
    Oncol Rep. 2018 Jan 4. doi: 10.3892/or.2018.6190.
    PubMed     Text format     Abstract available

  79. YIN G, Zeng B, Peng Z, Liu Y, et al
    Synthesis and application of 131I-fulvestrant as a targeted radiation drug for endocrine therapy in human breast cancer.
    Oncol Rep. 2018 Jan 11. doi: 10.3892/or.2018.6212.
    PubMed     Text format     Abstract available

  80. WANG YW, Zhang W, Ma R
    Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
    Oncol Rep. 2018 Jan 10. doi: 10.3892/or.2018.6205.
    PubMed     Text format     Abstract available

  81. KASORN A, Loison F, Kangsamaksin T, Jongrungruangchok S, et al
    Terrein inhibits migration of human breast cancer cells via inhibition of the Rho and Rac signaling pathways.
    Oncol Rep. 2018 Jan 4. doi: 10.3892/or.2018.6189.
    PubMed     Text format     Abstract available


    PLoS One

  82. PAUL B, Royston KJ, Li Y, Stoll ML, et al
    Impact of genistein on the gut microbiome of humanized mice and its role in breast tumor inhibition.
    PLoS One. 2017;12:e0189756.
    PubMed     Text format     Abstract available

  83. TSAI HP, Huang SF, Li CF, Chien HT, et al
    Differential microRNA expression in breast cancer with different onset age.
    PLoS One. 2018;13:e0191195.
    PubMed     Text format     Abstract available

  84. KHALIS M, Charbotel B, Chajes V, Rinaldi S, et al
    Menstrual and reproductive factors and risk of breast cancer: A case-control study in the Fez region, Morocco.
    PLoS One. 2018;13:e0191333.
    PubMed     Text format     Abstract available

  85. LI T, Zhao J, Yang J, Ma X, et al
    Correction: A Meta-Analysis of the Association between ESR1 Genetic Variants and the Risk of Breast Cancer.
    PLoS One. 2018;13:e0191579.
    PubMed     Text format     Abstract available

  86. HILDENBRAND G, Metzler P, Pilarczyk G, Bobu V, et al
    Dose enhancement effects of gold nanoparticles specifically targeting RNA in breast cancer cells.
    PLoS One. 2018;13:e0190183.
    PubMed     Text format     Abstract available

  87. BROMBERG SE, Moraes PRAF, Ades F
    Prime incision: A minimally invasive approach to breast cancer surgical treatment-A 2 cohort retrospective comparison with conventional breast conserving surgery.
    PLoS One. 2018;13:e0191056.
    PubMed     Text format     Abstract available

  88. HANLEY JA, Hannigan A, O'Brien KM
    Mortality reductions due to mammography screening: Contemporary population-based data.
    PLoS One. 2017;12:e0188947.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  89. DEVIGNES CS, Aslan Y, Brenot A, Devillers A, et al
    HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice.
    Proc Natl Acad Sci U S A. 2018 Jan 16. pii: 1718009115.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: